Study title: Cipro pediatric observational study.interim analysis/ A prospective, open-label, non-randomized, naturalistic, long-term safety surveillance, observational study of either ciprofloxacin (either as oral suspension, oral tablets or sequential IV oral therapy or purely IV therapy) or a non-quinolone antibiotic (either as oral suspension, oral tablets or sequential IV oral therapy or purely IV therapy) in the treatment of pediatric patients with infectious diagnoses.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Bacterial Infections and Mycoses [C01] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: CIPROFLOXACIN | |||||
| ATC code: | |||||
| Document link: Bayer Pharma_Ciprofloxacin_100225_study_synopsis.pdf | |||||
| Document date: 2011-09-07 | |||||
| Study number: BAY-O9867-100225 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | Y | |